Allergy Therapeutics PLC Result of Annual General Meeting (9657H)

TIDMAGY

RNS Number : 9657H

Allergy Therapeutics PLC

08 December 2020

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Result of Annual General Meeting

8 December 2020 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that, with the exception of resolution 10, which failed to carry, all other resolutions proposed at the 2020 Annual General Meeting ("AGM") were duly passed by shareholders. Voting was conducted by way of a poll.

Resolutions 1 to 9 (inclusive) were proposed as ordinary resolutions and resolution 10 was proposed as a special resolution. The results of the poll are outlined in the table below.

The Board acknowledges the failure to pass resolution 10 and is disappointed in this outcome. The Board considers the flexibility afforded by these authorities to be in the best interests of the Company and shareholders and notes that this resolution has received support at previous AGMs. However, the Board remains committed to continuing an open and transparent dialogue and will, accordingly, seek to continue to engage with shareholders regarding their views in this area.

 
                                                                         Total Votes   % of 
 Resolution                  For:          %age    Against:      %age     Cast          ISC    Withheld 
 1. to receive 
  a copy of the 
  Annual Report 
  for the year ended 
  30 June 2020               556,845,254     100             0       0   556,845,254   87.03      26,857 
                            ------------  ------  ------------  ------  ------------  ------  ---------- 
 2. To approve 
  the Directors' 
  Remuneration Report        554,801,389   99.64     1,990,053    0.36   556,791,442   87.02      80,669 
                            ------------  ------  ------------  ------  ------------  ------  ---------- 
 3. To re-appoint 
  Manuel Llobet 
  as a Director              556,845,611     100             0       0   556,845,611   87.03      26,500 
                            ------------  ------  ------------  ------  ------------  ------  ---------- 
 4. To re-appoint 
  Nicolas Wykeman 
  as a Director              556,821,111   99.99        25,000    0.01   556,846,111   87.03      26,000 
                            ------------  ------  ------------  ------  ------------  ------  ---------- 
 5. To re-appoint 
  Steve Smith as 
  a Director                 554,199,787   99.53     2,636,967    0.47   556,836,754   87.02      35,357 
                            ------------  ------  ------------  ------  ------------  ------  ---------- 
 6. To re-appoint 
  Peter Jensen as 
  a Director                 554,200,287    99.6     2,211,900     0.4   556,412,187   86.96     459,924 
                            ------------  ------  ------------  ------  ------------  ------  ---------- 
 7. To re-appoint 
  Grant Thornton 
  LLP as auditors 
  of the Company             554,851,201   99.64     2,007,553    0.36   556,858,754   87.03      13,357 
                            ------------  ------  ------------  ------  ------------  ------  ---------- 
 8. To authorise 
  the Directors 
  to determine the 
  Auditors remuneration      556,787,942   99.99        25,000    0.01   556,812,942   87.02      59,169 
                            ------------  ------  ------------  ------  ------------  ------  ---------- 
 9. To authorise 
  the Directors 
  to allot the unissued 
  share capital 
  up to a specified 
  amount (s.551)             281,855,864    50.8   272,997,694    49.2   554,853,558   86.71   2,018,553 
                            ------------  ------  ------------  ------  ------------  ------  ---------- 
 10. Special Resolution: 
  To disapply pre-emption 
  provisions of 
  s.561(1) of the 
  Companies Act 
  2006 up to a specified 
  amount                     281,828,810   50.61   274,980,390   49.39   556,809,200   87.02      62,911 
                            ------------  ------  ------------  ------  ------------  ------  ---------- 
 

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Deardon, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser

[e-mail]

Stern Investor Relations, Inc.

[phone]

Christina Tartaglia

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGKKFBQQBDDDBK

(END) Dow Jones Newswires

December 08, 2020 09:42 ET (14:42 GMT)